Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 10, Issue 6, Pages 771-780Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2014.904747
Keywords
bioimaging; hematological malignancy; invasive pulmonary aspergillosis; monoclonal antibody; PET; MRI; radioimmunotherapy; stem cell transplant; vaccine
Categories
Funding
- European Commission [HEALTH.2013.12-1, 602820]
Ask authors/readers for more resources
Invasive pulmonary aspergillosis (IPA) caused by the ubiquitous environmental fungus Aspergillus is a frequently fatal lung disease of immunocompromised humans accounting for more than 200,000 infections each year, with an associated mortality rate of 30-90%. This review addresses the current status of IPA diagnosis and treatment and the urgent need to develop accurate, non-invasive strategies for identifying pulmonary infections in the ever-expanding population of immune deficient patients at risk of acquiring opportunistic fungal infections including hematological malignancy and hematopoetic stem cell transplant patients. Recent advances in the use of an Aspergillus-specific monoclonal antibody, JF5, for point-of-care diagnosis of IPA using lateral-flow technology is examined, as is its use in PET/MRI bioimaging and radio-immunotherapy using radionuclide-labeled single chain antibody fragments, Fab fragments, and a fully humanized JF5 derivative.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available